Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder

To see complete record on, please visit this link

Id: NCT01046630

Organisation Name: AstraZeneca

Overal Status: Completed

Start Date: December 2009

Last Update: October 13, 2014

Lead Sponsor: AstraZeneca

Brief Summary: The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.

  • Depression

Total execution time in seconds: 0.3005039691925